Scientific presentations

Webcast positive OCEAN topline results

May 25, 2021

Oncopeptides presented positive topline results from the phase 3 OCEAN and hosted a webcast Tuesday May 25, 2021, at 11:00 (CET). 

Read more

Post ASH 2020 – webcast & presentation

December 9, 2020

Oncopeptides hosted a webcast on Wednesday, December 9th at 14:00 (CET) to provide an update regarding data presented at the ASH annual meeting. The webcast was recorded and hosted by CEO Marty J Duva...

Read more

ANCHOR presentation at ASH 2020

December 6, 2020

Oncopeptides presented new data from phase 2 ANCHOR combination study in multiple myeloma the 62<sup>nd</sup> American Society of Hematology virtual annual meeting ASH, December 6, 2020. See presentat...

Read more

The presentation to the webcast – top-line data HORIZON

June 16, 2020

Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients. On June 16 at 10:00 (CET), CEO Jakob Lindberg comments on the to...

Read more

EHA 2020 – posters

June 15, 2020

Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients as well as several other posters during EHA. See posters below.

Read more

Presentation webcast HORIZON Topline results

March 26, 2020

Oncopeptides hosted a webcast to present the HORIZON study data and provided a general clinical update March 26, 2020. The webcast was recorded and can be followed via the link:

Read more

Presentation – Webcast melflufen’s mechanism of action

January 24, 2020

Oncopeptides will host a webcaston Monday, January 27th 2020 were CEO Jakob Lindberg will present and explain melflufen’s mechanism of action. The presentation will be available below just before the ...

Read more

Post ASH Webcast 2019

December 10, 2019

Webcast post ASH, at 13.00 CET, December 10, 2019.

Read more

ASH 2019

December 7, 2019

Poster presentations held at ASH 2019.

Read more

ASH Abstracts 2019

November 6, 2019

Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019.

Read more

Lymphoma & Myeloma Congress 2019

October 24, 2019

In New York, USA. Oncopeptides presented three posters at the Lymphoma & Myeloma Congress 2019. See the Posters below.

Read more

European Society for Medical Oncology 2019 (ESMO) September 27th, 2019

September 30, 2019

Oncopeptides presented one poster at the ESMO meeting in Barcelona, Spain. See the Poster below.

Read more

IMW 2019 oral presentation

September 15, 2019

Oncopeptides presented new interim data in RRMM Patients with Extramedullary Disease (EMD) from the Pivotal Phase 2 Horizon-study at the 17th International Myeloma Workshop (IMW) meeting in Boston, Ma...

Read more

IMW 2019 Posters

September 14, 2019

Oncopeptides presented two poster at the 17th International Myeloma Workshop (IMW) meeting in Boston, Massachusetts, USA. See the Posters below.

Read more

Society of Hematologic Oncology (SOHO) 2019

September 11, 2019

At the Society of Hematologic Oncology (SOHO) 2019 Annual Meeting in Houston, TX, USA, clinical trial data from two of our trials HORIZON and ANCHOR were presented. In an oral presentation, data from ...

Read more

EHA 2019 – presentations and articles

June 24, 2019

During 2019 European Hematology Association (EHA) Congress, Oncopeptides presented updated interim data from the ongoing phase 1/2 ANCHOR study, data from its phase 1/2 O-12-M1 study and updated inter...

Read more

ASCO 2019 – presentations and articles

June 21, 2019

During 2019 ASCO General Meeting (American Society of Clinical Oncology), Oncopeptides presented new data from phase 1/2 O-12-M1 trial evaluating melflufen in RRMM. These data was presented by Profess...

Read more

Post EHA – webcast regarding data update

June 17, 2019

Oncopeptides hosted a webcast on Monday, 17 June at 09:00 (CET) to review and update presentations from European Hematology Association (EHA) meeting. It was presented by CEO Jakob Lindberg and member...

Read more

EHA 2019 – Oral Presentation

June 16, 2019

Professor Paul G. Richardson held an oral presentation of the study HORIZON at EHA 2019 on 16 June.

Read more

EHA 2019 – posters

June 14, 2019

Poster presentations at EHA June 14th, 2019.

Read more

2019 ASCO Annual Meeting – poster

June 3, 2019

New data from Oncopeptides phase 1/2 O-12-M1 trial evaluating melflufen in RRMM presented at 2019 ASCO annual meeting by Professor Paul G. Richardson.

Read more

Oncopeptides hosting a symposium at the upcoming EHA, 13 June 2019

May 27, 2019

Oncopeptides hosts a symposium at the upcoming EHA 2019. The symposium takes place on Thursday 13 June, 2019. See the invitation below, welcome to join us.

Read more

EHA Abstracts 2019

May 16, 2019

Upcoming presentations at EHA:

Read more

ASCO Abstract 2019

May 15, 2019

Oncopeptides has a poster presentation of data from its Phase 1/2 O-12-M1 study at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4 in Chicago. The st...

Read more

AACR 2019 – Posters

April 3, 2019

At the AACR (American Association for Cancer Research) Annual Meeting 2019 Oncopeptides presented two Posters for the studies ANCHOR and HORIZON.

Read more

ASH 2018 – presentations and articles

December 10, 2018

During the American Hematology Meeting (ASH), Oncopeptides presented data from two ongoing studies, ANCHOR and HORIZON. These presentations as well as publications in the media are presented below. Th...

Read more

Professor Paul G. Richardson presentation at ASH 2018 – The HORIZON study

December 3, 2018

Professor Paul G. Richardson presentation at ASH 2018 – The HORIZON study.

Read more

60th ASH Annual Meeting & Exposition – Poster ANCHOR

December 1, 2018

ANCHOR poster. Oncopeptides presents the first interim data with melflufen (Ygalo®) from the ongoing phase I/II study ANCHOR at the 60th ASH meeting in San Diego, California, USA (December 1, 2018).

Read more

ASH Abstracs 2018

November 1, 2018

Oncopeptides to present updated data from the two ongoing trials ANCHOR and HORIZON in patients with RRMM at ASH in December 2018. The abstract data cut for ANCHOR was July 18th and for HORIZON, May 1...

Read more

Presentation at 23rd Congress of The European Hematology Association (EHA)

June 15, 2018

The updated phase II-data show a clinical data set with an Overall Response Rate (ORR) of 32.1% and a Clinical Benefit Rate (CBR) of 39.3% with Ygalo® in relapsed/refractory multiple myeloma patients ...

Read more

ASH summary Webcast

December 13, 2017

Oncopeptides had a press conference on December 13.

Read more

59th ASH Annual Meeting & Exposition – Posters

December 9, 2017

Horizon Poster (9 Dec 2017) and O-12-M1 Poster (10 Dec 2017).

Read more

American Society of Hematology (ASH) – Abstract

November 1, 2017

Read more

Press release -

Oncopeptides withdraws Pepaxto® in US, scale down organization and focus on R&D

Read press release
Events Oncopeptides

Upcoming events

View calendar

Oncopeptides via e-mail

Get our latest updates straight to your inbox. Unsubscribe at anytime.

This site is protected by reCAPTCHA & the Google Privacy Policy & Terms of Service  apply.